Browsing by Author "Uzay, Ant"
Now showing items 1-6 of 6
-
Comparison of outcomes of total body irradiation (TBI) vs non-TBI conditioning regimens in acute lymphoblastic leukemia for allogeneic transplantation
Beköz, Hüseyin Saffet; Sevindik, Ömür Gökmen; Özçelik, Tülay; Arat, Mutlu; Hindilerden, İpek Yonal; Beşışık, Sevgi Kalayoğlu; Nalcacı, Meliha; Uzay, Ant; Kartı, Süleyman Sami; Kıvanç, Demet; Sargın, Deniz (Nature Publishing Group, 2019)... -
Effects of neuromuscular electrical stimulation combined with resistance exercises on muscle strength in adult hematological cancer patients: A randomized controlled study
Safran, Elif Esma; Mutluay, Fatma; Uzay, Ant (Elsevier Ltd, 2022)Objective: We compared the effects of resistance exercise (REx) and resistance exercise combined with neuromuscular electrical stimulation (NMES+REx) on muscle strength, functional lower extremity strength, and mobility ... -
Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
Ferhanoğlu, Burhan; Gülbaş, Zafer; Uzay, Ant; Özcan, Muhit; Özkalemkaş, Fahir; Dal, Mehmet Sinan; Kalyon, Hakan; Akay, Olga Meltem; Deveci, Burak; Bekoz, Hüseyin; Sevindik, Ömür Gökmen; Toptaş, Tayfur; Yılmaz, Asu Fergün; Koyun, Derya; Alkış, Nihan; Birtaş Ateşoğlu, Elif (American Society of Hematology, 2022)Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response ... -
Ibrutinib as a promising treatment for pulmonary complications due to refractory chronic graft versus host disease
İlhan, Osman; Cengiz Seval, Güldane; Uzay, Ant; Kaya, Emin; Öztürk, Zübeyde Nur; Deveci, Burak; Yavaşoğlu, İrfan; Ural, Ali Uğur; Beköz, Hüseyin Saffet; Ayli, Meltem; Sevindik, Ömür Gökmen; Civriz Bozdağ, Sinem; Kurt Yüksel, Meltem; Gülbas, Zafer (Elsevier Science Inc, 2020)Introduction: Despite major improvements in allogeneic hematopoetic stem cell transplantation form matched related/ unrelated donor over last decades, chronic graft-versus-host disease (cGVHD) is still the leading cause ... -
Myelodysplastic syndrome with t(9;22)(p24;q11.2), a BCR-JAK2 fusion: case report and review of the literature
Kantarcıoğlu, Bülent; Kaygusuz Atagündüz, Işık; Uzay, Ant; Toptaş, Tayfur; Fıratlı Tuğlular, Tulin; Bayık, Mahmut (Springer Japan, 2015)The human JAK2 gene is mainly targeted by two types of genetic lesions that play roles in the pathogenesis of hematologic malignancies: intragenic mutations and chromosomal translocations. Chromosomal translocations of ... -
Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: A real-world data from Turkey
Dal, Mehmet Sinan; Ulu, Bahar Uncu; Uzay, Ant; Akay, Olga Meltem; Beşışık, Sevgi; Yenerel, Mustafa Nuri; Çelik, Serhat; Kaynar, Leylagül; Yücel, Orhan Kemal; Deveci, Burak; Sönmez, Mehmet; Mehtap, Özgür; Beköz, Hüseyin Saffet; Sunu, Cenk; Salim, Ozan; Ulaş, Turgay; Kartı, Sami; Altuntaş, Fevzi; Ferhanoğlu, Burhan; Tuğlular, Tülin Fırat (Springer, 2023)Polatuzumab vedotin (Pola) with bendamustine and rituximab (BR) is a promising option for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). We analyzed the data of 71 R/R DLBCL patients who had ...
